Graviton Bioscience Gains FDA IND Clearance for GV101
New York, New York, August,11, 2026 Graviton Bioscience Corporation, a clinical-stage biotechnology company developing selective ROCK2 inhibitors, has announced...
Orphan Disease
Advertisement
Waters Strengthens Clinical Diagnostics with Xevo XR Innovation
MILFORD, Mass., July 27, 2026 Waters Corporation has introduced the Xevo™ TQ Absolute XR IVD Mass Spectrometer, expanding its...
BioMarin Partners n-Lorem on First ReNU Syndrome Therapy
SAN RAFAEL, Calif. & SAN DIEGO, July 27, 2026 BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a...
CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial
CAMBRIDGE, Mass., July 27, 2026 CAMP4 Therapeutics announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration...
Vanda Gains EMA Orphan Status for Imsidolimab in GPP
WASHINGTON, July 16, 2026 Vanda Pharmaceuticals has announced that the Committee for Orphan Medicinal Products (COMP) at the European...
Advertisements
Boehringer Ingelheim Wins EU Approval for JASCAYD
INGELHEIM, Germany, July 17, 2026 Boehringer Ingelheim has announced that the European Commission (EC) has granted marketing authorization for...
CureDuchenne and Tevard Biosciences Advance DMD Therapy
NEWPORT BEACH, Calif., May 20, 2026 CureDuchenne announced a new partnership expansion with Tevard Biosciences to accelerate development of...
Palvella Therapeutics Wins 2026 PACT Healthcare & Life Sciences Company of the Year Award
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
Advertisement
